Use access key #2 to skip to page content.
$14.44 -0.14 (-0.96%)
7/18/2008 4:00 PM

Alkermes, Inc. (ALKS)

CAPS Rating:
****

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ALKS

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

139 Outperforms
5 Underperforms
 

All-Stars

50 Outperforms
2 Underperforms
 

Wall Street

5 Outperforms
1 Underperforms
 

Players bullish on ALKS are also bullish on:

Players bearish on ALKS are also bearish on:

Ticker Tags

Drug Delivery (22), Options Backdating (?) (115), Biotechnology (293), Small Cap (1922)
Suggest a tag

Alkermes, Inc. At A Glance

Current Price: $14.44
Last Trade Time: 7/18/2008 4:00 PM
Open: $14.56
Previous Close: $14.58
Daily Range: $14.38 - $14.60
52-Week Range: $10.32 - $18.78
Volume: 1,016,702
Market Cap: $1.39B
P/E Ratio: 8.78
Compare Our Special Broker Offers!

Stock Trends

ALKS VS S&P 500 (SPY)

ALKS 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for ALKS

More Headlines...

Top Bull Pitch

Recs

4

Alkermes, Inc. (ALKS)

Avatar NetscribeBiotech (75.73) Submitted: 2/13/07 6:33 AM

Alkermes, Inc. (Alkermes) is a biotechnology company that develops products based on drug delivery technologies. The company has two commercial products: Risperdal Consta (risperidone), for use in schizophrenia and Vivitrol, a once-monthly injection for the treatment of alcohol dependence.

Alkernes...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 27 :   1 2 3 4 5 Next »

Recs

0

 (ALKS)

Avatar lulamae12 (< 20) Submitted: 6/08/08 8:27 PM : Outperform Start Price: $12.64 ALKS Score: 22.27

ALKS, a name you will be hearing due to the development of several new drugs. ALKS is currently working with its partner, Johnson and Johnson, in the development of a drug to to treat rapidly recurring Bi-Polar disorder. Alks has also developed a drug to treat pulmonary obstructive disease. The other drug that is showing great strides is one that is taken only once a week for diabetes control. Most of the drugs currently used for this are injectable at least once a day if not more. This compares to the ALKS drug that is inhaled. People with diabetes would be ecstatic to see this drug on the market.
A restructuring program has been initiated at ALKS. That with the new drugs mean BUY NOW! .......before the price goes up.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALKS)

Avatar JonAtkins57 (< 20) Submitted: 5/28/08 5:03 PM : Outperform Start Price: $12.12 ALKS Score: 28.48

Market Cap > 1B and < 2.5B
P/E Ratio < 20
Div Yield % < 1
Current Ratio > 0
Last Price < 20
Net Profit Margin % > 25

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALKS)

Avatar EMG114 (96.39) Submitted: 5/20/08 9:24 PM : Outperform Start Price: $13.71 ALKS Score: 17.06

There is high expectations in some circles about this company since many are predicting stronger sales of its schizophrenia drug Risperdal Consta. Not only that but, Alkermes' diabetes drug Exenatide LAR will get attention at a diabetes conference in June since competing drug candidates are thought to be less effective and thus, will not be featured in the conference. All this can boost ALKS' sales and stocks...

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALKS)

Avatar odmonk (85.35) Submitted: 5/10/08 3:56 AM : Outperform Start Price: $13.03 ALKS Score: 20.30

This may be a slow grower at first; dropping its inhaled insulin product and slimming costs appropriately should make the next set of guidance more attractive to investors for the near term. Revisit if "stuff happens".

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ALKS)

Avatar GyroDynasty (89.77) Submitted: 5/07/08 5:22 PM : Outperform Start Price: $12.87 ALKS Score: 22.03

Little Monster

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 27 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 6 of 6  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackMerrimanCo < 20 06/05/08 Outperform NS $12.50+15.52%-9.16%+24.68
TrackRothCapital 45.45 04/22/08 Outperform NS $11.31+27.67%-8.70%+36.37
TrackBofASec 96.91 12/18/07 Outperform NS $14.59-1.03%-13.59%+12.56
TrackJPMorgan 93.70 11/09/07 Outperform NS $13.49+7.04%-13.48%+20.52
TrackFBR 90.59 11/03/06 Outperform NS $14.91-3.15%-8.17%+5.02
TrackJimCramer 82.55 07/31/06 Underperform 3W $17.16-15.85%-1.12%+14.73

Results 1 - 6 of 6  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners